Side-by-side · Research reference

ThymalinvsTirzepatide

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AHuman-MechanisticDraft12/40 cited

BFDA-ApprovedVerified14/45 cited

Thymalin

Immune restorer · Russian peptide bioregulator

5–10 mgPer cycle doseKhavinson 2002

HumanMechanisticKhavinson 2002

HoursHalf-life (est)

IM · Daily for 5–10 days · 1-2×/year

Tirzepatide

GIP+GLP-1 Dual Agonist · FDA-Approved

2.5–15 mgWeekly doseZEPBOUND (tirzepatide) injecti 2023

20.9%Body-weight ↓Jastreboff 2022

~5 daysHalf-lifeZEPBOUND (tirzepatide) injecti 2023

SQ · Abdomen / thigh / arm · Once weekly

01Mechanism of Action

Parameter

Thymalin

Tirzepatide

Primary target

T-cell precursors + thymus-axis maturation pathwayKhavinson 2002

GIP receptor (GIPR) + GLP-1 receptor (GLP-1R)Frias 2018

Pathway

Modulation of T-cell differentiation + thymic hormone restoration in age-involuted thymusKhavinson 2002

Dual GIPR/GLP-1R agonism → ↑insulin (glucose-dependent), ↓glucagon, ↓gastric emptying, ↓appetite, ↑energy expenditure (via GIP component)Jastreboff 2022 Frias 2018

Downstream effect

Restored T-cell populations, improved immune surveillance, reduced infection rates in elderlyKhavinson 2002

Profound glycemic improvement and weight reduction; cardiometabolic benefitsJastreboff 2022

Feedback intact?

—

Glucose-dependent insulin release preserves physiological feedback

Origin

Polypeptide fraction isolated from calf thymus extractKhavinson 2002

39-AA peptide with C-20 fatty-acid acylation. Single molecule with balanced GIP + GLP-1 affinityFrias 2018

Antibody development

—

02Dosage Protocols

Parameter

Thymalin

Tirzepatide

Standard dose

5–10 mg / day IM × 5–10 daysKhavinson 2002

—

Frequency

Once daily during cycle

—

Lower / starter dose

2.5 mg / day

—

Evidence basis

Russian clinical + in vitroKhavinson 2002

FDA-approved · Phase 3 RCTs (SURMOUNT, SURPASS)Jastreboff 2022 ZEPBOUND (tirzepatide) injecti 2023

Duration

5–10 day cycles, 1–2× per year

Indefinite for chronic indication

Reconstitution

Saline or bacteriostatic water

Pre-filled commercial pen. Research vial: bacteriostatic water per label.

Timing

Morning preferred

Once weekly, any time of day

Half-life

Hours (estimated)

~5 days (116 h)ZEPBOUND (tirzepatide) injecti 2023

Standard dose (T2D)

—

5–15 mg / weekZEPBOUND (tirzepatide) injecti 2023

Standard dose (weight)

—

5, 10, or 15 mg / week (titrated)ZEPBOUND (tirzepatide) injecti 2023 Jastreboff 2022

Titration schedule

—

2.5 mg → +2.5 mg every 4 weeks → 15 mg max

Slower titration mitigates GI side effects.

04Side Effects & Safety

Parameter

Thymalin

Tirzepatide

Injection site reaction

Mild erythema at IM site

Mild erythema, pruritus

Allergic reaction

Rare hypersensitivity to bovine-derived polypeptide

—

Autoimmune flare

Theoretical risk in active autoimmune disease

—

Long-term safety

Limited Western data

—

Pregnancy / OB

Avoid

Contraindicated

GI symptoms

—

Nausea, vomiting, diarrhea (common, dose-dependent)Jastreboff 2022

Pancreatitis risk

—

Rare; discontinue if suspectedZEPBOUND (tirzepatide) injecti 2023

Thyroid C-cell tumours

—

Boxed warning — contraindicated in MEN2 / MTC historyZEPBOUND (tirzepatide) injecti 2023

Hypoglycemia

—

Low as monotherapy; risk with sulfonylureas / insulin

Gallbladder events

—

Increased cholelithiasis

Diabetic retinopathy

—

Rapid glycemic improvement may transiently worsen

Absolute Contraindications

Thymalin

·Pregnancy / breastfeeding
·Bovine protein hypersensitivity

Tirzepatide

·MTC personal or family history; MEN2
·Pregnancy / breastfeeding
·Hypersensitivity to tirzepatide

Relative Contraindications

Thymalin

·Active autoimmune disease
·Concurrent immunosuppressant therapy

Tirzepatide

·Severe gastroparesis
·History of pancreatitis
·Diabetic retinopathy

05Administration Protocol

Parameter

Thymalin

Tirzepatide

1. Reconstitution

Add 1–2 mL saline or bacteriostatic water per 10 mg vial.

Commercial: pre-filled pen / vial. Research lyophilised: bacteriostatic water per label.

2. Injection site

Intramuscular — deltoid or gluteal. Rotate sites.

SQ — abdomen, thigh, or upper arm. Rotate weekly.

3. Timing

Morning preferred during cycle.

Once weekly, same day. Day change allowed if ≥3 days separate doses.

4. Storage

Lyophilised: refrigerate, light-protected. Reconstituted: use immediately.

Refrigerate 2–8 °C unopened. Room temp ≤30 °C up to 21 days after first use.

5. Needle

23–25G, 25–38 mm IM needle.

Pen-supplied. Research vial: 27–31G insulin syringe.

06Stack Synergy

Thymalin

+ Thymosin α-1

Moderate

View Thymosin α-1 →

Thymalin is a polypeptide complex; Thymosin α-1 is a single purified peptide. Both target the thymus-axis but at different levels — Thymalin restores broad thymic signaling; Tα-1 provides a specific molecular activator. Anecdotally combined for elderly immune support.

Thymalin: 5–10 mg IM · daily × 7 days
Thymosin α-1: 1.6 mg SQ · 2× weekly during the cycle
Primary benefit: Broad thymic restoration + targeted immune activation

Khavinson 2002 Camerini 2001

Tirzepatide

— no documented stacks